GE HealthCare Technologies Inc. Declares Quarterly Dividend of $0.03 (NASDAQ:GEHC)

GE HealthCare Technologies Inc. (NASDAQ:GEHC) announced a quarterly dividend on Wednesday, September 18th, Zacks reports. Stockholders of record on Friday, October 18th will be paid a dividend of 0.03 per share on Friday, November 15th. This represents a $0.12 annualized dividend and a dividend yield of 0.13%. The ex-dividend date of this dividend is Friday, October 18th.

GE HealthCare Technologies has a dividend payout ratio of 2.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect GE HealthCare Technologies to earn $4.72 per share next year, which means the company should continue to be able to cover its $0.12 annual dividend with an expected future payout ratio of 2.5%.

GE HealthCare Technologies Trading Up 2.4 %

Shares of NASDAQ GEHC opened at $90.62 on Friday. GE HealthCare Technologies has a fifty-two week low of $62.35 and a fifty-two week high of $94.50. The company’s 50 day simple moving average is $83.64 and its 200 day simple moving average is $83.31. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.06 and a quick ratio of 0.82. The firm has a market capitalization of $41.36 billion, a P/E ratio of 26.50, a P/E/G ratio of 3.26 and a beta of 1.17.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.02. GE HealthCare Technologies had a return on equity of 25.26% and a net margin of 8.10%. The company had revenue of $4.84 billion for the quarter, compared to analysts’ expectations of $4.88 billion. During the same quarter in the prior year, the business posted $0.92 EPS. The business’s revenue was up .5% compared to the same quarter last year. On average, analysts predict that GE HealthCare Technologies will post 4.26 EPS for the current year.

Insider Transactions at GE HealthCare Technologies

In other news, CEO Thomas J. Westrick sold 2,750 shares of GE HealthCare Technologies stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $80.78, for a total value of $222,145.00. Following the completion of the sale, the chief executive officer now directly owns 17,509 shares in the company, valued at $1,414,377.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group started coverage on GE HealthCare Technologies in a report on Thursday, May 30th. They issued a “neutral” rating and a $87.00 target price on the stock. JPMorgan Chase & Co. began coverage on GE HealthCare Technologies in a research note on Monday, September 9th. They issued a “neutral” rating and a $90.00 price objective on the stock. Redburn Atlantic raised GE HealthCare Technologies to a “strong-buy” rating in a research report on Thursday, August 1st. BTIG Research upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Wednesday. Finally, Stifel Nicolaus started coverage on shares of GE HealthCare Technologies in a research report on Tuesday, August 6th. They set a “buy” rating and a $100.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $95.00.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.